Holen Sie sich die Stockscreener-App
1.12
0.00%
0.00
Femasys Inc Aktie (FEMY) Neueste Nachrichten
H.C. Wainwright maintains Buy rating on Femasys on secureing strategic Spain distribution - Investing.com
Femasys Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Femasys secures distribution partnerships for commercialization of FemaSeed - TipRanks
Femasys Secures Strategic Distribution Partnerships for - GlobeNewswire
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market - StockTitan
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device - Yahoo Finance
Items Tagged with 'Femchec' - BioWorld Online
Femasys gains FDA clearance for new diagnostic tool FemChec - Investing.com India
Femasys gains FDA clearance for new diagnostic tool FemChec - Investing.com
Femasys Femchec receives FDA clearance - BioWorld Online
Femasys gains FDA clearance for new diagnostic tool FemChec By Investing.com - Investing.com UK
Femasys Inc. Receives U.S. FDA Clearance to Market - GlobeNewswire
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check - StockTitan
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting - GlobeNewswire
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting - Yahoo Finance
Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI - MSN
Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI - Yahoo Finance
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance UK
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Femasys Inc (FEMY)’s stock price range in the last year - US Post News
Stocks of Femasys Inc (FEMY) are poised to climb above their peers - SETE News
Femasys Releases Updated Corporate Presentation Online - TipRanks
Femasys Inc (FEMY) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Femasys secures CE mark certification for FemVue MINI solution - Yahoo Finance
FEMYFemasys Inc. Latest Stock News & Market Updates - StockTitan
Femasys gains European and Canadian approval for FemVue MINI - Investing.com
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution - GlobeNewswire
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution - Yahoo Finance
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters - GlobeNewswire
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters - StockTitan
Femasys Inc. at August 20th Virtual Investor Summit Microcap Event - StockTitan
Femasys (NASDAQ:FEMY) Stock Quotes, Forecast and News Summary - Benzinga
Chardan Capital Lowers Femasys (NASDAQ:FEMY) Price Target to $10.00 - Defense World
Femasys (NASDAQ:FEMY) PT Lowered to $12.00 at HC Wainwright - Defense World
Femasys Second Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
FEMY’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Femasys stock target cut to $12 amid sales headwinds By Investing.com - Investing.com Canada
Femasys stock target cut to $12 amid sales headwinds - Investing.com India
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update - GlobeNewswire
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update - Yahoo Finance
Femasys stock target cut to $12 amid sales headwinds - Investing.com
Richard Spector Named Chief Commercial Officer At Femasys - MPO-mag
Femasys Inc (FEMY) stock analysis: A comprehensive overview - US Post News
Femasys Inc. (NASDAQ:FEMY) Sees Significant Increase in Short Interest - American Banking and Market News
Femasys Inc. (NASDAQ:FEMY) Short Interest Update - Defense World
Femasys shareholders elect director, ratify accounting firm - Investing.com
Femasys shareholders elect director, ratify accounting firm By Investing.com - Investing.com
Femasys CEO Talks Results of the Femaseed Pivotal Trial and the History of Fembloc Birth Control - Pharmaceutical Executive
HPV Testing and Pap Smear Testing Market Price Trends Analysis Roche Holding AG, QIAGEN, Hologic, Femasys ... - Economica
Shareholders May Be More Conservative With Femasys Inc.'s (NASDAQ:FEMY) CEO Compensation For Now - Simply Wall St
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution - Quantisnow
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch - Quantisnow
Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference - Quantisnow
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control - Quantisnow
Femasys Inc. MDSAP Surveillance Audit Successfully Completed - Quantisnow
Femasys' FemCath Intrauterine Catheter Receives Product Approval in Canada - Quantisnow
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update - Quantisnow
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine - Quantisnow
Femasys Inc. Regains Compliance with Nasdaq Listing Requirements - Quantisnow
Femasys Inc. to Showcase Four Products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting - Quantisnow
Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution - Quantisnow
Femasys' FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada - Quantisnow
Femasys' FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada - Quantisnow
Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device - Quantisnow
Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control - Quantisnow
1.27%
1.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):